Pertuzumab (Perjeta®) for Adjuvant HER2 positive breast cancer

Assessment Status Assessment Process Complete
Drug Pertuzumab
Brand Perjeta®
Indication Is licensed for the adjuvant treatment, in combination with trastuzumab and chemotherapy, of adult patients with HER2-positive breast cancer at high risk of recurrence.
Assessment Process
Rapid review commissioned 01/06/2018
Rapid review completed 22/06/2018
Rapid review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of pertuzumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 22/06/2018
Pre-submission consultation with Applicant 31/07/2018
Full submission received from Applicant 14/09/2018
Preliminary review sent to Applicant 13/11/2018
Follow-up to preliminary review sent to Applicant 27/11/2018
NCPE assessment re-commenced 03/12/2018
Factual accuracy sent to Applicant 11/01/2019
NCPE assessment re-commenced 18/01/2019
NCPE assessment completed 31/01/2019
NCPE assessment outcome The NCPE recommends that pertuzumab (in combination with trastuzumab and chemotherapy) for the adjuvant treatment of adult patients with HER2-positive breast cancer at high risk of recurrence (defined here as patients with node-positive or hormone receptor-negative disease), not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.

Technical Summary

This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.